Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013980 | 1.00 | PKM (0.71) | PKMALDH1A1HTTPOLBMAPT | |
| Bromide SCHEMBL3970603 | 0.98 | PKM (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL651924 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL5955341 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL9122576 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL8134887 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| Hydrochloric Acid SCHEMBL3244036 | 0.96 | ALDH1A1 (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL8631891 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL3419433 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| Propane SCHEMBL8394288 | 0.95 | PKM (0.65) | PKMALDH1A1HTTPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590952-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | CATEXEL LTD (GB) | 2017-01-18 | — | — | EP | claimed |
| US-8907082-B2 | 1,2-bis-(4,7-dimethyl-1,4,7-triazacyclonon-1-yl)-ethane and intermediate for the synthesis of same | CATEXEL LIMITED (GB) | 2014-12-09 | — | — | US | claimed |
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LIMITED (GB) | 2013-10-03 | — | — | US | claimed |
| US-12577371-B2 | Oxidatively curable coating composition | MILLIKEN INDUSTRIALS LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-3818115-B1 | OXIDATIVELY CURABLE COATING COMPOSITION | MILLIKEN INDUSTRIALS LTD (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20210221975-A1 | OXIDATIVELY CURABLE COATING COMPOSITION | Borchers Catalyst (UK) Limited (GB) | 2021-07-22 | — | — | US | disclosed |
| EP-3176155-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LTD (GB) | 2019-09-25 | — | — | EP | disclosed |
| EP-3176155-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | Catexel Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-2590952-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | CATEXEL LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| US-8907082-B2 | 1,2-bis-(4,7-dimethyl-1,4,7-triazacyclonon-1-yl)-ethane and intermediate for the synthesis of same | CATEXEL LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| WO-2001062262-A1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CONCAT, LTD. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5739022-A | CLEAVAGE PHOSPHORUS, OXYGEN LINKAGE FO NUCLEIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577371-B2 | Oxidatively curable coating composition | TET1, JMJD6, SETDB1 | PKM 3294/4885ALDH1A1 235/4885HTT 1271/4885 |
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | DHPS, CYP51A1, BID | PKM 2369/4885ALDH1A1 451/4885HTT 3156/4885 |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | SKP1, ADCY7, ERBB2 | PKM 2340/4885ALDH1A1 1714/4885HTT 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.